Newest MATH+ Protocol

Have you heard of the MATH+ protocol to treat COVID-19? One of its creators, Dr. Joseph Varon, who leads the COVID-19 unit at United Memorial Medical Center (UMMC) in Houston, has been trying to get the word out about it since the start of the pandemic. "We have options for patients now. We just need to make those options available," he said, speaking with broadcast journalist Ivory Hecker.1 Hecker has a story in her own right, as she was fired from FOX 26 Houston in June 2021 after she interrupted a live news segment to tell viewers the station had prohibited her from sharing certain information, adding that she's "not the only reporter being subjected to this."2 Censorship is an ongoing problem that's reached unprecedented levels during the pandemic, and is the reason why you probably haven't heard of the MATH+ protocol, despite its immense success in saving lives over the last year. Varon has been at the frontlines throughout, marking his 366th consecutive day treating COVID-19 patients on March 20, 2021.3 From March 20, 2021, to May 21, 2021, there were 1,293 hospitalized COVID-19 patients at United Memorial Medical Center. Eighty-six of them died, resulting in a 6.7% death rate. That's about half the 12.5% death rate for hospitalized COVID-19 patients reported by the National Center for Health Statistics over the same period.4 MATH+ Protocol Saves Lives, but Media Is Ignoring It Early on in the pandemic, five critical care physicians formed the Front Line COVID-19 Critical Care Working Group (FLCCC), which developed the highly effective COVID-19 treatment protocol known as MATH+. Varon was among them, as was Dr. Paul Marik, a critical care doctor at Sentara Norfolk General Hospital in East Virginia. The protocol for hospitalized patients was initially based on the following: Intravenous Methylprednisolone High-dose intravenous Ascorbic acid (vitamin C) Plus optional treatments Thiamine, zinc and vitamin D Full dose low molecular weight Heparin In the beginning, only supportive care was offered to COVID-19 patients. Even today, people with COVID-19 are told to stay home and isolate until they're lacking oxygen, a recommendation that Marik believes is costing lives, since early treatment with MATH+ is so effective:5 "While we may not have the best answers, we do have some answers and to tell people to stay at home and isolate so they go blue is an absurdity that's actually causing lots of damage because we are now waiting for the virus to, in some people, cause the cytokine storm. And when they arrive with that state it is very difficult to reverse it and stop it and bring them back." The MATH+ protocol led to high survival rates. Out of more than 100 hospitalized COVID-19 patients treated with the MATH+ protocol as of mid-April 2020, only two died. Both were in their 80s and had advanced chronic medical conditions.6 But according to Varon, despite their unusual successes, reporters weren't interested in why the patients at his hospital were more likely to survive.7 The physicians behind MATH+ are clear that their protocols are fluid and change in response to the data. As such, there have been two major changes since MATH+ was first released, one involving ivermectin and another involving hydroxychloroquine (HCQ). Ivermectin Added to MATH+ Ivermectin was added as a core medication in FLCCC's protocols for the prevention and treatment of COVID-19 in October 2020.8 Ivermectin — a broad-spectrum antiparasitic that also has anti-inflammatory activity — has been found to reduce COVID-19 mortality by 81%.9 The drug is also safe, inexpensive and widely available, with decades of clinical usage suggesting it has a "high margin of safety."10 By December 2020, FLCCC, noting the extreme success of the drug, called for widespread adoption of ivermectin, both as a prophylactic and for the treatment of all phases of COVID-19.11,12 In one prevention trial, 58 volunteers took 12 milligrams of ivermectin once per month for four months. Only four (6.96%) came down with mild COVID-19 symptoms during the May through August 2020 trial period.13 In comparison, 44 of 60 health care workers (73.3%) who had declined the medication were diagnosed with COVID-19. In June 2021, Varon and colleagues published a review in the American Journal of Therapeutics, which included meta-analyses based on 18 randomized controlled treatment trials of ivermectin in COVID-19.14 The results were impressive, showing:15 Large, statistically significant reductions in mortality, time to clinical recovery and time to viral clearance when used for treatment Significantly reduced risks of contractive COVID-19 with regular ivermectin use The data are so strong that, at the India Institute of Medical Sciences, all health care workers now take two 0.3 mg/kg doses of ivermectin 72 hours apart, then repeat the dose monthly to prevent COVID-19.16 And in regions that have implemented ivermectin distribution c

Newest MATH+ Protocol

Have you heard of the MATH+ protocol to treat COVID-19? One of its creators, Dr. Joseph Varon, who leads the COVID-19 unit at United Memorial Medical Center (UMMC) in Houston, has been trying to get the word out about it since the start of the pandemic. "We have options for patients now. We just need to make those options available," he said, speaking with broadcast journalist Ivory Hecker.1

Hecker has a story in her own right, as she was fired from FOX 26 Houston in June 2021 after she interrupted a live news segment to tell viewers the station had prohibited her from sharing certain information, adding that she's "not the only reporter being subjected to this."2

Censorship is an ongoing problem that's reached unprecedented levels during the pandemic, and is the reason why you probably haven't heard of the MATH+ protocol, despite its immense success in saving lives over the last year. Varon has been at the frontlines throughout, marking his 366th consecutive day treating COVID-19 patients on March 20, 2021.3

From March 20, 2021, to May 21, 2021, there were 1,293 hospitalized COVID-19 patients at United Memorial Medical Center. Eighty-six of them died, resulting in a 6.7% death rate. That's about half the 12.5% death rate for hospitalized COVID-19 patients reported by the National Center for Health Statistics over the same period.4

MATH+ Protocol Saves Lives, but Media Is Ignoring It

Early on in the pandemic, five critical care physicians formed the Front Line COVID-19 Critical Care Working Group (FLCCC), which developed the highly effective COVID-19 treatment protocol known as MATH+. Varon was among them, as was Dr. Paul Marik, a critical care doctor at Sentara Norfolk General Hospital in East Virginia. The protocol for hospitalized patients was initially based on the following:

  • Intravenous Methylprednisolone
  • High-dose intravenous Ascorbic acid (vitamin C)
  • Plus optional treatments Thiamine, zinc and vitamin D
  • Full dose low molecular weight Heparin

In the beginning, only supportive care was offered to COVID-19 patients. Even today, people with COVID-19 are told to stay home and isolate until they're lacking oxygen, a recommendation that Marik believes is costing lives, since early treatment with MATH+ is so effective:5

"While we may not have the best answers, we do have some answers and to tell people to stay at home and isolate so they go blue is an absurdity that's actually causing lots of damage because we are now waiting for the virus to, in some people, cause the cytokine storm. And when they arrive with that state it is very difficult to reverse it and stop it and bring them back."

The MATH+ protocol led to high survival rates. Out of more than 100 hospitalized COVID-19 patients treated with the MATH+ protocol as of mid-April 2020, only two died. Both were in their 80s and had advanced chronic medical conditions.6 But according to Varon, despite their unusual successes, reporters weren't interested in why the patients at his hospital were more likely to survive.7

The physicians behind MATH+ are clear that their protocols are fluid and change in response to the data. As such, there have been two major changes since MATH+ was first released, one involving ivermectin and another involving hydroxychloroquine (HCQ).

Ivermectin Added to MATH+

Ivermectin was added as a core medication in FLCCC's protocols for the prevention and treatment of COVID-19 in October 2020.8 Ivermectin — a broad-spectrum antiparasitic that also has anti-inflammatory activity — has been found to reduce COVID-19 mortality by 81%.9 The drug is also safe, inexpensive and widely available, with decades of clinical usage suggesting it has a "high margin of safety."10

By December 2020, FLCCC, noting the extreme success of the drug, called for widespread adoption of ivermectin, both as a prophylactic and for the treatment of all phases of COVID-19.11,12 In one prevention trial, 58 volunteers took 12 milligrams of ivermectin once per month for four months.

Only four (6.96%) came down with mild COVID-19 symptoms during the May through August 2020 trial period.13 In comparison, 44 of 60 health care workers (73.3%) who had declined the medication were diagnosed with COVID-19. In June 2021, Varon and colleagues published a review in the American Journal of Therapeutics, which included meta-analyses based on 18 randomized controlled treatment trials of ivermectin in COVID-19.14 The results were impressive, showing:15

  • Large, statistically significant reductions in mortality, time to clinical recovery and time to viral clearance when used for treatment
  • Significantly reduced risks of contractive COVID-19 with regular ivermectin use

The data are so strong that, at the India Institute of Medical Sciences, all health care workers now take two 0.3 mg/kg doses of ivermectin 72 hours apart, then repeat the dose monthly to prevent COVID-19.16 And in regions that have implemented ivermectin distribution campaigns, associated reductions in case fatality rates results.17 According to the review:18

"Finally, the many examples of ivermectin distribution campaigns leading to rapid population-wide decreases in morbidity and mortality indicate that an oral agent effective in all phases of COVID-19 has been identified."

Marik believes that a mass distribution program of ivermectin, together with melatonin, vitamin D and aspirin, could end the pandemic. By assuming everyone is infected and treating with this safe combination of inexpensive compounds, Marik says, "We'll eliminate SARS-CoV-2. It will be gone."19 This isn't likely to happen, though, due to "economic and political factors that benefit from the ongoing pandemic."20

HCQ Replaced With Quercetin

HCQ, a zinc ionophore, was part of the MATH+ protocol for the first six months of the pandemic. (They have recently swapped quercetin for HCQ.) At this time, the death rate for COVID-19 patients at Varon's UMMC was 4.4%, compared to a death rate of about 20% at other hospitals.21

Hecker first spoke with Varon about HCQ in August 2020, and he spoke favorably about using the controversial drug, noting that out of more than 300 COVID-19 patients treated at UMMC, they had a 95% success rate.22

Misinformation and outright lies were spun about HCQ, including fabricated research, in an apparent effort to suppress and prevent its widespread use. Other physicians, including Dr. Vladimir Zelenko, a practicing physician in a Jewish community in Monroe, New York, have had great success using HCQ for COVID-19.23

However, in June 2020, the National Institutes of Health halted a clinical trial of HCQ after stating that, while the drug wasn't harmful, it also wasn't beneficial to hospitalized patients.24

Backlash ensued following the NIH announcement, and FLCCC phased out the use of HCQ in its protocols. Their latest I-MASK+ protocol, updated June 30, 2021,25 recommends quercetin instead. Quercetin, also a zinc ionophore, is an over-the-counter alternative to HCQ and works much like HCQ does. According to Marik:26

"Experimental and early clinical data (published in high impact journals) suggests that this compound has broad antiviral properties (including against coronavirus) and acting at various steps in the viral life cycle. It also appears to be a potent inhibitor of heat shock proteins (HSP 40 and 70) which are required for viral assembly."

Ivermectin Continues To Be Censored, US on 'Media Lockdown'

In the video above, Hecker speaks with several recovered COVID-19 patients who received the MATH+ protocol. One, Manuel Espinoza, a urologist from Texas, was on a slow decline using the conventional COVID protocols. Then his wife found out about the MATH+ protocol online, and Espinoza was emergency airlifted to UMMC. "Within hours" of the treatment his health had turned around, he said, and "within days, just immense improvement."27

Yet, Varon said that every time he mentioned ivermectin on social media, "he went to Facebook jail." Reporters also told him, multiple times, that they were banned from reporting on certain COVID-19 drug treatments.28 Similar censorship was experienced by Dr. Pierre Kory, who was also a part of the group that formed FLCCC.

On December 8, 2020, Kory testified to the Senate Committee on Homeland Security and Governmental Affairs, which held a hearing on "Early Outpatient Treatment: An Essential Part of a COVID-19 Solution." He called on the NIH, CDC and FDA to review the expansive data on ivermectin to prevent COVID-19, keep those with early symptoms from progressing and help critically ill patients recover:29,30

Despite his impassioned pleas and astonishing science to back them up, the treatment was not only ignored by the committee but promptly eviscerated.31 Meanwhile, media reports claimed ivermectin was unproven and the World Health Organization also refused to endorse it.

YouTube removed Kory's testimony, which had nearly 9 million views, calling it a danger to the community.32 Kory says that while his research on ivermectin has gotten lots of attention worldwide, it's gotten zero in the U.S. — "U.S. is on a media lockdown," he said.33 Varon agreed, telling Hecker that "no one" is asking about the MATH+ protocol. "Right now everyone is interested in vaccination."34

MATH+ Protocol Is Available in 23 Languages

FLCCC's I-MASK+ protocol can be downloaded in full,35 giving you step-by-step instructions on how to prevent and treat the early symptoms of COVID-19. FLCCC also has protocols for at-home prevention and early treatment, called I-MASS, which involves ivermectin, vitamin D3, a multivitamin and a digital thermometer to watch your body temperature in the prevention phase and ivermectin, melatonin, aspirin and antiseptic mouthwash for early at-home treatment.

Household or close contacts of COVID-19 patients may take ivermectin (18 milligrams, then repeat the dose in 48 hours) for post-exposure prevention.36 FLCCC also has a management protocol — I-RECOVER37 — for long haul COVID-19 syndrome. The protocols are translated into 23 different languages to provide widespread, free access to this lifesaving information, including how to get ivermectin.38

FLCCC remains hopeful that ivermectin will be formally adopted into national or international COVID-19 treatment guidelines in the near future. But, as Hecker noted, the inexpensive medication faces a major hurdle:39

"Had there been an existing known, safe and effective treatment for COVID-19, Emergency Use Authorization of a vaccine for the virus would be prohibited by law. Could that have been part of the motivation for the strange censorship of certain COVID-19 treatments that we witnessed over the past year at news and social media corporations?"

Source : Mercola More   

What's Your Reaction?

like
0
dislike
0
love
0
funny
0
angry
0
sad
0
wow
0

Next Article

Juul Buys Out 1 Issue of Health Journal for Positive Studies

The American Journal of Health Behavior1 published a special May/June 2021 edition dedicated solely to Juul. In essence, Juul Labs sponsored the entire issue of this national journal and devoted it to research funded or written by the company. Juul began as a Silicon Valley darling in 2007.2 But the history of Juul Labs started two years before that when Stanford graduates James Monsees and Adam Bowen conceived "The Rational Future of Smoking," which was their graduate thesis and prediction of the future.3 After graduation the two founded Ploom Inc. and in 2012,4 the company introduced Pax, which became a popular way of consuming cannabis. By 2015 the company was renamed Pax Labs and they introduced the Juul e-cigarette. In 2017, Pax labs separated from Juul Labs to focus on other products, leaving Juul Labs to manufacture and distribute nicotine e-cigarettes. By 2018 they were under investigation by the U.S. Food and Drug Administration for sales to underaged users. In 2019, experts across the country recognized a unique lung infection and injury associated with vaping.5 By February 18, 2020, there were 2,807 people who had been hospitalized and 68 confirmed deaths. Investigations for underage sales, lung injuries and the sale of contaminated Juul pods6 prompted the company to spend 2020 in what The New York Times reported as a “reset” mode.7 As the FDA considers the future of the company, Juul is trying prove the product has public health benefit. JUUL Paid This Journal to Publish Their ‘Science’ The FDA has set September 9, 2021, as a deadline for deciding whether products offered by Juul Labs have enough public health benefit to stay on the market.8 Juul has recorded a loss of sales of $500 million and cut their workforce by 75% since 2019.9 The company that was once valued at $38 billion, is now valued under $5 billion. While waiting for the FDA to deliberate, the company teamed with Piney Associates and the Centre for Substance Use Research (CSUR) to develop documentation that purportedly demonstrates the vaping device is a safer alternative to cigarettes.10 Once the papers were completed, Juul spent $51,000 with the American Journal of Health Behavior to publish 11 studies they funded or helped write in a special edition publication.11 The company paid an additional $6,500 so the information would have open access on the internet. The published works are meant to support the company's premarket tobacco product application, which the company has not made public. Once the Juul issue was published, the journal’s editor-in-chief, Elbert D Glover, Ph.D., retired, without announcing his plans. Before leaving, he said the journal had followed their standard protocol before publishing the studies — but three editorial board members still resigned in protest. The journal published conflict of interest disclosures12 which showed that all the studies were either written by scientists employed by Juul Labs or the research was funded by the company.13 The Company Pays to Squash Bad Press The company is intent on creating positive press and squashing negative press as they wait for the FDA to make its decision. According to The New York Times,14 if the company survives the end of 2021, they are facing thousands of lawsuits. Fourteen states and the District of Columbia are seeking money to combat what has become a vaping crisis in the youth. The Justice Department has the company under criminal investigation and there is multidistrict litigation in the California Federal Court. The company’s first hurdle was to address the lawsuit in North Carolina filed by the North Carolina attorney general. According to Business Insider, Juul Labs agreed to pay $40 million and change their business practices to avoid a jury trial over questions of whether the company allegedly marketed their product to teens.15 In addition to the financial award, CNN reported some of the stipulations that the company must follow as stated by North Carolina Attorney General Josh Stein. These include:16 Cannot sell any flavored nicotine pods in North Carolina without authorization from the FDA Cannot use marketing strategies aimed at young people Cannot use influencer advertising, outdoor ads near schools or sponsor concerts or sporting events Cannot use most social media advertising Cannot use anyone under age 35 in advertising Cannot claim the e-cigarettes are safer or better for health than combustible cigarettes The company must use a barcode age-verification system of identification and the system must be tested using mystery shoppers at 1,000 stores each year Online sales are restricted to no more than two devices per month and 10 per year CNN reported Juul stated restrictions are in line with their desire to curb underage smoking. A company spokesperson from Juul Labs spoke with a CNN reporter about how the award would

Juul Buys Out 1 Issue of Health Journal for Positive Studies

The American Journal of Health Behavior1 published a special May/June 2021 edition dedicated solely to Juul. In essence, Juul Labs sponsored the entire issue of this national journal and devoted it to research funded or written by the company.

Juul began as a Silicon Valley darling in 2007.2 But the history of Juul Labs started two years before that when Stanford graduates James Monsees and Adam Bowen conceived "The Rational Future of Smoking," which was their graduate thesis and prediction of the future.3

After graduation the two founded Ploom Inc. and in 2012,4 the company introduced Pax, which became a popular way of consuming cannabis. By 2015 the company was renamed Pax Labs and they introduced the Juul e-cigarette. In 2017, Pax labs separated from Juul Labs to focus on other products, leaving Juul Labs to manufacture and distribute nicotine e-cigarettes.

By 2018 they were under investigation by the U.S. Food and Drug Administration for sales to underaged users. In 2019, experts across the country recognized a unique lung infection and injury associated with vaping.5 By February 18, 2020, there were 2,807 people who had been hospitalized and 68 confirmed deaths.

Investigations for underage sales, lung injuries and the sale of contaminated Juul pods6 prompted the company to spend 2020 in what The New York Times reported as a “reset” mode.7 As the FDA considers the future of the company, Juul is trying prove the product has public health benefit.

JUUL Paid This Journal to Publish Their ‘Science’

The FDA has set September 9, 2021, as a deadline for deciding whether products offered by Juul Labs have enough public health benefit to stay on the market.8 Juul has recorded a loss of sales of $500 million and cut their workforce by 75% since 2019.9 The company that was once valued at $38 billion, is now valued under $5 billion.

While waiting for the FDA to deliberate, the company teamed with Piney Associates and the Centre for Substance Use Research (CSUR) to develop documentation that purportedly demonstrates the vaping device is a safer alternative to cigarettes.10

Once the papers were completed, Juul spent $51,000 with the American Journal of Health Behavior to publish 11 studies they funded or helped write in a special edition publication.11 The company paid an additional $6,500 so the information would have open access on the internet.

The published works are meant to support the company's premarket tobacco product application, which the company has not made public. Once the Juul issue was published, the journal’s editor-in-chief, Elbert D Glover, Ph.D., retired, without announcing his plans.

Before leaving, he said the journal had followed their standard protocol before publishing the studies — but three editorial board members still resigned in protest. The journal published conflict of interest disclosures12 which showed that all the studies were either written by scientists employed by Juul Labs or the research was funded by the company.13

The Company Pays to Squash Bad Press

The company is intent on creating positive press and squashing negative press as they wait for the FDA to make its decision. According to The New York Times,14 if the company survives the end of 2021, they are facing thousands of lawsuits.

Fourteen states and the District of Columbia are seeking money to combat what has become a vaping crisis in the youth. The Justice Department has the company under criminal investigation and there is multidistrict litigation in the California Federal Court.

The company’s first hurdle was to address the lawsuit in North Carolina filed by the North Carolina attorney general. According to Business Insider, Juul Labs agreed to pay $40 million and change their business practices to avoid a jury trial over questions of whether the company allegedly marketed their product to teens.15

In addition to the financial award, CNN reported some of the stipulations that the company must follow as stated by North Carolina Attorney General Josh Stein. These include:16

Cannot sell any flavored nicotine pods in North Carolina without authorization from the FDA

Cannot use marketing strategies aimed at young people

Cannot use influencer advertising, outdoor ads near schools or sponsor concerts or sporting events

Cannot use most social media advertising

Cannot use anyone under age 35 in advertising

Cannot claim the e-cigarettes are safer or better for health than combustible cigarettes

The company must use a barcode age-verification system of identification and the system must be tested using mystery shoppers at 1,000 stores each year

Online sales are restricted to no more than two devices per month and 10 per year

CNN reported Juul stated restrictions are in line with their desire to curb underage smoking. A company spokesperson from Juul Labs spoke with a CNN reporter about how the award would be distributed, saying:17

"We look forward to working with Attorney General Stein and other manufacturers on the development of potential industry-wide marketing practices based on science and evidence. In addition, we support the Attorney General's desire to deploy funds to generate appropriate science to support North Carolina's public health interventions to reduce underage use."

As the company publicly agrees with the restrictions to their marketing and sales, their federal lobbying has remained robust. According to the Center for Responsive Politics,18 which tracks giving in the political arena, Juul spent $3.9 million in 2020, down $400,000 from 2019. Altria, the tobacco company that bought 35% of Juul in 201819 spent $10.6 million in 2020, which is $150,000 more than they spent in 2019.20

The Marlboro Man Wants the FDA to Trust JUUL

In September 2019, the CEO of Juul Labs stepped down and KC Crosthwaite, longtime tobacco executive, stepped into the role.21 Once installed, Crosthwaite stopped some of the controversial lobbying campaigns, closed many of Juul’s foreign markets, took mint flavored pods off the market and suspended U.S. advertising.22

In a company email he alluded to the fact that Juul must place earning the trust of the consumer at the center of what they do. However, as The New York Times23 points out, each of these changes was made at gunpoint. And the gun was pointed by the FDA, which threatened to shut down their business.

Matthew L Myers, president of the Campaign for Tobacco-Free Kids, characterized the business relationship between Altria and Juul Labs this way: “The Marlboro man rode into Juul and now wants us to trust them.”24

At the end of Monsees’ and Bowen’s thesis presentation at Stanford, they played a video during which a user of the new product said, “This product is the greatest thing I have ever encountered in my life. I will smoke this with enthusiasm and develop a nicotine habit that will follow me to my grave.”25

A journalist from the Verge summarized the situation after an interview with the author of “The Devil’s Playbook: Big Tobacco, Juul, and the Addiction of a New Generation,” writing that the podcast listeners would recognize other industry themes:26

“There’s a big industry that’s slow to adapt, there’s a startup that’s moving fast and breaking things, there are regulators around the world who don’t quite know what to do, and at the center of it all, there’s a big question about our society’s relationship with a product that might be bad for people — and that people still want.”

JUUL Purposely Sold Tainted Product and Marketed It to Kids

Siddharth Breja, formerly Juul's senior vice president for global finance, claims in a lawsuit he filed in the U.S. District Court for the Northern District of California that he was fired in 2019 in retaliation for criticizing the sale of at least 1 million contaminated and expired mint-flavored nicotine pods by Juul.27

The type of contamination or its source was not revealed in the lawsuit. Breja was quoted in The New York Times saying Juul “has jeopardized and continues to jeopardize public health and safety and the lives of millions of consumers, many of them children and teens.”28 The reporter wrote:29

“Mr. Breja detailed a culture of indifference to safety and quality-control issues among top executives at the company and quoted the then-chief executive Kevin Burns saying at a meeting in February: 'Half our customers are drunk and vaping' and wouldnʼt 'notice the quality of our pods.'”

Breja’s lawsuit alleged the contaminated mint-flavored pods were the result of decisions at Juul Labs to fill a huge demand for that flavor. This happened after the FDA pulled all other flavored pods in retail stores but continued to allow Juul to sell mint and menthol.

It wasn't long before the demand outstripped the supply. In the complaint, Breja said then-chief executive Kevin Burns told employees, “You need to have an IQ of 5 to know that when customers don’t find mango, they buy mint.”30

Once Breja learned of the contaminated pods, and that they could not be recovered, he urged the company to issue a recall or a warning. One week later, Breja was fired. Despite the proximate action, Juul spokesperson Ted Kwong dismissed the claims and said he was fired “because [Breja] failed to demonstrate the leadership qualities needed in his role.”31

Can Super-Addictive Nicotine Reduce Your Desire to Smoke?

David Kessler was head of the FDA from 1990 to 1997 during the tobacco investigation. The Los Angeles Times quotes him saying, “Addiction is central to the business model. With their nicotine salts, Juul has found the Holy Grail.”32

The Los Angeles Times reviewed more than 3,000 pages of internal company records released through the Freedom of Information Act showing Juul used research done by Reynolds Laboratories more than four decades before the release of JuulSalts.

Myers told the Los Angeles Times reporter, “Reynolds succeeded in developing the technology, but never really succeeded in turning it into a transformative breakthrough. Juul did that.”33

The data from the Freedom of Information Act release also showed Juul collected information on how to maximize nicotine delivery and literature collected by Reynold’s laboratory on how the drug impacts adolescent brains. The idea was to develop a new generation of nicotine addicts. Robert Jackler, Stanford University researcher, focused on teen e-cig use, commenting:34

“Reynolds successfully engineered this formula, but it was Juul that ultimately vaporized it — and achieved what Big Tobacco never could. They studied Reynold’s literature, took advantage of it, and addicted a new generation of American youth.”

At a 2018 tech startup conference, Monsees said on stage, “Certainly, the nicotine salt chemistry was one of the big breakthroughs.”35

The premise behind any good business model is to acquire and then keep customers. The food processed industry does this by ascertaining the “bliss point” in their product, which is the exact amount of sugar, salt and fat to optimize taste and make the product so perfectly engineered that you want more and more.36

Despite Juul Labs’ public assertion that their product is designed to be self-limited as a means of getting people to stop smoking combustible cigarettes, this model would soon put them out of business. Instead, you only have to look at the product itself and the history of the company’s push toward addiction to know the objective is to garner more customers and make more money — not to lose customers.

Source : Mercola More   

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.